Publication

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland.

Journal Paper/Review - Feb 9, 2022

Units
PubMed
Doi
Contact

Citation
Perrig K, Krupka N, Jordi S, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka S, Juillerat P, Burri E, Zimmermann D, Maillard M, Sulz M, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol 2022; 15:17562848221074188.
Type
Journal Paper/Review (English)
Journal
Therap Adv Gastroenterol 2022; 15
Publication Date
Feb 9, 2022
Issn Print
1756-283X
Pages
17562848221074188
Brief description/objective

Tumor necrosis factor (TNF) inhibitors have improved treatment of ulcerative colitis (UC), but loss of response remains a frequent problem. The anti-TNF agent, golimumab, was approved in Switzerland for the treatment of UC in 2014. This study aims to summarize the experience of golimumab in a real-world setting in Switzerland.